Study design and participants
MagnetisMM-1 is a first-in-human, open-label, multicenter, phase 1 study (This study was conducted in accordance with the Declaration of Helsinki and the International Conference on Harmonization guidelines for Good Clinical Practice. All patients provided written informed consent. The study protocol and relevant documents were approved by an independent institutional review board or ethics committee at each investigative center. Patient safety was monitored jointly by investigators and a safety assessment committee established by the sponsor.